TITLE

New strategies for treatment of pulmonary fibrosis

AUTHOR(S)
Phan, S H
PUB. DATE
April 1995
SOURCE
Thorax;Apr1995, Vol. 50 Issue 4, p415
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66066488

 

Related Articles

  • Acute Exacerbations in Idiopathic Pulmonary Fibrosis. Crowley, Searnus P.; Kelly, Peter; Egan, Jim J. // Annals of Internal Medicine;2/7/2006, Vol. 144 Issue 3, p218 

    A letter to the editor is presented commenting on the treatment of patients with idiopathic pulmonary fibrosis.

  • International guidelines launched for treatment of idiopathic pulmonary fibrosis.  // British Journal of Hospital Medicine (17508460);Aug2015, Vol. 76 Issue 8, p441 

    The article reports the launching by an international group of leading respiratory societies as of August 2015 of updated guidelines on the treatment of idiopathic pulmonary fibrosis. According to group leader, Professor Ganesh Raghu of University of Washington, the recommended treatments should...

  • Update on diagnosis and treatment of idiopathic pulmonary fibrosis. Baddini-Martinez, José; Baldi, Bruno Guedes; da Costa, Cláudia Henrique; Jezler, Sérgio; Lima, Mariana Silva; Rufino, Rogério // Jornal Brasileiro de Pneumologia;set/out2015, Vol. 41 Issue 5, p454 

    Idiopathic pulmonary fibrosis is a type of chronic fibrosing interstitial pneumonia, of unknown etiology, which is associated with a progressive decrease in pulmonary function and with high mortality rates. Interest in and knowledge of this disorder have grown substantially in recent years. In...

  • pulmonary fibrosis. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p639 

    An encyclopedia entry for the term "pulmonary fibrosis" is presented. It refers to scarring and thickening of lung tissue as a result of previous lung inflammation. Its common symptom is shortness of breath. A chest X-ray confirms a pulmonary fibrosis diagnosis. Treatment for pulmonary fibrosis...

  • Breathing hope.  // Pharmaceutical Executive;Oct97, Vol. 17 Issue 10, p120 

    Reports that the US Food & Drug Administration has approved MoliChem Medicines' investigational new-drug application for duramycin as a treatment for cystic fibrosis and chronic obstructive pulmonary disease in the United States.

  • Molecular Mechanisms of Pulmonary Fibrosis and Current Treatment. Kuwano, Kazuyoshi; Hagimoto, Naoki; Hara, Nobuyuki // Current Molecular Medicine;Nov2001, Vol. 1 Issue 5, p551 

    Pulmonary fibrosis is a common response to various insults or injuries to the lung. Although there are various initiating factors or causes, the terminal stages are characterized by proliferation and progressive accumulation of connective tissue replacing normal functional parenchyma. The...

  • Mechanisms of Colchicine Effect in the Treatment of Asbestosis and Idiopathic Pulmonary Fibrosis. Addrizzo-Harris, D.J.; Harkin, T.J.; Tchou-Wong, K.M.; McGuinness, G.; Goldring, R.; Cheng, D.; Rom, D.W.N. // Lung;2002, Vol. 180 Issue 2, p61 

    The objective of this study was to evaluate the mechanisms of colchicine action in pulmonary fibrosis. The study included 10 patients with pulmonary fibrosis (idiopathic pulmonary fibrosis 5, asbestosis 4, and scleroderma 1) who had been admitted to Bellevue Hospital Center, a tertiary care...

  • Pulmonary fibrosis associated with hypersensitivity to gold salts. Geddes, D.M.; Brostoff, Jonathan // British Medical Journal;6/12/1976, Vol. 1 Issue 6023, p1444 

    Examines the association of pulmonary fibrosis with hypersensitivity to gold salts. Occurrence of pulmonary fibrosis during gold treatment; Correlation between lymphocyte transformation with adverse reaction to gold; Effects of gold treatment.

  • Pulmonary hypertension complicating pulmonary fibrosis: bad and ugly, but good to treat? Nathan, Steven D. // Thorax;Feb2014, Vol. 69 Issue 2, p107 

    The author reflects on a study that discusses complications associated with pulmonary hypertension (PH) such as pulmonary fibrosis. Topics discussed include addresses treatment of PH in idiopathic pulmonary fibrosis (IPF), treatment of pulmonary arterial hypertension (PAH) and role of six minute...

  • Glucose Intolerance in a Three-Year-Old Child With Cystic Fibrosis. Peden, Virginia H.; Powell, Keith R.; Rejent, Anthony J. // Clinical Pediatrics;Jan1974, Vol. 13 Issue 1, p10 

    Glucose intolerance preceding pulmonary disease in a child with cystic fibrosis is described. After glucose intolerance was controlled with tolbutamide, the pulmonary infection resolved. Early recognition and treatment of "diabetes" in children with cystic fibrosis is emphasized.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics